Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up.
about
Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive DiseaseSulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach.The management of superficial bladder cancer.Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer.Best practice in the treatment of nonmuscle invasive bladder cancer.Previous Bladder Cancer History in Patients with High-Risk, Non-muscle-invasive Bladder Cancer Correlates with Recurrence and Progression: Implications of Natural HistoryControversial issues and optimal management of stage T1G3 bladder cancer.Bacillus Calmette-Guérin in the management of superficial bladder cancer.Pros and cons of radical cystectomy in the treatment of T1G3 bladder cancer.Risk-adapted use of intravesical immunotherapy.The optimal management of T1 high-grade bladder cancer.The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer.Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer.Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment.Treatment and management of high-grade T1 bladder cancer: what should we do after second TUR?Impact of divergent differentiation in urothelial carcinoma on oncological outcome in patients with T1 high-grade bladder cancer.Introduction of 65 kDa antigen of Mycobacterium tuberculosis to cancer cells enhances anti-tumor effect of BCG therapy.Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder.Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder.
P2860
Q27011829-E29242EE-4BAB-4793-92F7-3B084B3AA13AQ30234740-EECBCEB2-6857-46A6-B3DA-15BCBE29C198Q34135229-7AEFB997-D19D-4CCC-933C-38A3F84438C3Q34435935-FE7C56C4-6D84-4C34-B021-8043215B74AFQ35688392-645F19EB-F32C-4614-8708-ACCA341CCF2CQ35862328-B350E00E-8B96-4967-AC15-3A0F48AF829EQ36573859-0F240240-1D2C-4378-A29A-3DA9332ACC70Q37197525-6E3935C4-3DF0-4529-9570-AF85212E2DF3Q37197530-76463876-AD9D-4AFC-9C23-3AE1215A4DAFQ37335474-8DF3D942-12B0-43E3-B7F7-AD0F61CC994AQ37472570-5E9D60B3-363C-4EE9-AEA3-5E5134617E4BQ37779813-3D0DD448-EEDE-4FC7-B242-50E2B6676D1FQ37813081-BE9A5CE9-B683-4CF1-A21C-B88700D93A02Q37833152-01FCE778-3EC0-478B-9682-152BC9A44B23Q38316336-41C6205D-C896-4DAC-9A99-00B4668B882AQ38882257-28B8D1D3-C6ED-47D8-86CC-E3337EDC708CQ40563204-AE2143D9-6811-4135-8F58-D045FDA16791Q43850878-AEB1A1CF-6E0B-47DC-8033-7FD2E0A1E1A4Q44282720-D8CB0804-9A80-49F6-B863-2A0F3EEA7F3CQ47264571-716CF8E0-6D55-4E30-9E36-2EC3EB6F01BDQ48107131-D9424CFD-1A05-4311-9B85-024F42155955Q51834265-9F561CCC-5760-4FB3-8242-8A157D130900
P2860
Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Intravesical bacille Calmette- ...... r therapy: a 7-year follow-up.
@ast
Intravesical bacille Calmette- ...... r therapy: a 7-year follow-up.
@en
type
label
Intravesical bacille Calmette- ...... r therapy: a 7-year follow-up.
@ast
Intravesical bacille Calmette- ...... r therapy: a 7-year follow-up.
@en
prefLabel
Intravesical bacille Calmette- ...... r therapy: a 7-year follow-up.
@ast
Intravesical bacille Calmette- ...... r therapy: a 7-year follow-up.
@en
P2093
P1433
P1476
Intravesical bacille Calmette- ...... er therapy: a 7-year follow-up
@en
P2093
P304
P356
10.1016/S0090-4295(99)00116-8
P407
P577
1999-08-01T00:00:00Z